[Drug perspectives in the treatment of invasive aspergillosis].
The frequency of infections caused by Aspergillus sp. is on the rise, and the mortality is high in the disseminated forms of the disease. Amphotericin B is theoretically the gold standard treatment, but remains inefficient in severely immunocompromised patients, particularly bone-marrow transplants. The interest of lipidic formulations of amphotericin B, triazoles, new antifungal drugs targeted on the fungal cell wall and immunomodulators is discussed.